General News

Sunitinib After Nephrectomy Benefits Some Patients with Advanced Kidney Cancer

October 2018, Vol 9, No 3 - In the Literature

Nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years. However, its role in treating patients with advanced disease in the era of targeted therapy has been brought into question. In the CARMENA study, researchers assessed the benefit of initial nephrectomy followed by targeted therapy with sunitinib (Sutent) in patients with metastatic kidney cancer versus the benefits provided by su­nitinib monotherapy. [ Read More ]

Talazoparib, a New PARP Inhibitor, Shows Significant Benefit in Patients with Breast Cancer and BRCA Mutation

October 2018, Vol 9, No 3 - In the Literature

Talazoparib, an oral investigational poly (ADP-ribose) polymerase (PARP) inhibitor, is currently being evaluated in advanced breast cancer with BRCA mutation and other cancer types. Talaz­oparib’s dual mechanism of action has the potential to induce tumor cell death by blocking PARP enzyme activity and trapping PARP on the sites of DNA damage. [ Read More ]

In the Literature – November 2016

November 2016, Vol 7, No 10 - In the Literature

  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Adding Daratumumab to Standard Regimen Extends Progression-Free Survival in Patients with Multiple Myeloma
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]

In the Literature – October 2016

October 2016, Vol 7, No 9 - In the Literature

In This Article Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma Addition of Elective Neck Dissection Reduces Overall Costs in Patients with Oral Cavity Cancer 70-Gene Signature Assists Clinicians in Breast Cancer Treatment Decision-Making Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Many patients with B-cell acute lymphoblastic leukemia (ALL) who achieve complete remission will have disease relapse. Because of the poor prognosis for adults with relapsed ALL, investigators assessed the efficacy and safety [ Read More ]